Open Access: View PDF

DOI: DOI: http://dx.doi.org/10.21088/ijog.2321.1636.6418.6

Abstract

Aim: To study the effect of low dose mifepristone on the leiomyoma volume reduction, leiomyoma-related symptoms and endocrinal profile in patients with
symptomatic leiomyoma.

Setting: Tertiary care hospital

Material and Methods: Sixty-two patients with symptomatic uterine leiomyoma were recruited and distributed to receive 10 mg mifepristone (Group 1) and placebo capsule containing 10 mg lactose (Group 2) OD for 3 months. Baseline leiomyomarelated symptoms and leiomyoma volume was recorded, followed by monthly assessment for three months. Baseline hormonal profile was done and repeated at the end of therapy.

Main outcome measure (s): The reduction in the uterine leiomyoma volume, effect of mifepristone on the leiomyomarelated symptoms and the hormonal levels.

Result (s): There was a significant percentual decrease (p = 0.000) in the total leiomyoma volume in the mifepristone-treated group, -58.36±8.92% (mean ±S.D), compared with the control group, 0%. Mifepristone treatment significantly reduced the bleeding days (p = 0.000) by causing amenorrhea in all the patients (100%). There was a significant improvement in the leiomyoma-related symptoms and the hormonal levels remained unchanged.

Conclusion: Mifepristone may offer an effective conservative treatment option for women with symptomatic uterine leiomyoma and the associated pronounced uterovaginal bleeding. It is efficacious in reducing leiomyoma volume and leiomyoma-related symptoms of menorrhagia and dysmenorrhoea.

Keywords: Mifepristone; Leiomyoma; Leiomyoma Volume; Leiomyoma Related
Symptoms.

Corresponding Author : Neha Varun, Assistant Professor, Department of Obstetrics and Gynecology, Hamdard institute of Medical Sciences and Research, Hamdard Nagar, New Delhi, Delhi 110062, India